Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a recent and fast growing class of oral anti-hyperglycaemic agents available to treat patients with type 2 diabetes (T2DM) [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.